SRI International Lipoxygenase Inhibitor Patent, Apr 15, 2026

European Patent Office published application EP4125874A1 for lipoxygenase inhibitors on April 15, 2026. The patent names SRI International as applicant with inventors JONG Ling, NG Raymond, and COLLINS Nathan. IPC classifications include C07D 209/88, C07D 403/12, A61K 31/403, and A61K 31/407, with designated states spanning 31 European jurisdictions including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Affected parties include pharmaceutical manufacturers and researchers working on lipoxygenase inhibition therapies. The publication establishes priority rights for SRI International in these chemical compound classes across designated EPO member states. Companies developing similar compounds should review the published claims to assess potential licensing needs or design-around considerations.